

## Curriculum Vitae

Name **Dr Stephen Gerard O'BRIEN**  
Date of Birth 18<sup>th</sup> February 1964  
Nationality British  
GMC registration no. 3240090  
JCHMT accreditation 17<sup>th</sup> June 1997  
Current position Senior Lecturer in Haematology, University of Newcastle  
Honorary Consultant Haematologist, Royal Victoria Infirmary,  
Newcastle. Appointed March 1999.  
Work address Department of Haematology, University of Newcastle, Royal  
Victoria Infirmary, Newcastle NE1 4LP  
Telephone +44 191 282 0568  
Fax +44 191 222 5524  
Email s.g.o'brien@ncl.ac.uk

### 1. Education

1974-1981 William Hulme's Grammar School, Manchester  
1981-1987 University of Manchester Medical School  
*Honours in Pathology and Community Medicine, Distinction in  
Surgery, Mark Lascelles Surgery Prize at finals*  
1984-1985 Intercalated Honours BSc Pathology  
1986 Elective period at Stanford University Medical School, Palo Alto,  
California, USA.

### 2. Qualifications


BSc (Hons) Pathology	University of Manchester	July 1985
MB ChB	University of Manchester	July 1987
FRCP (UK)	Royal College of Physicians	November 1990
MRCPath	Royal College of Pathologists	March 1997
PhD	Imperial College, University of London	May 1998

### 3. Previous appointments

Dates	Position	Qualifications obtained
1987-91	House jobs (Withington & Manchester Royal Infirmary), SHO in Medicine at MRI.	MRCP (FRCP, 2004)
1991-93	Registrar. Department of Haematology, Hammersmith Hospital, London	MRCPath part 1
1993-96	Research Fellow (Honorary SR). LRF Adult Leukaemia Unit, Hammersmith Hospital (Imperial College, London. (Prof JM Goldman)	PhD
1996-99	Clinical Lecturer (Honorary SR) Department of Haematology, University of Wales College of Medicine	MRCPath part 2

## 4. Selected recent publications

- 4.1.1. Kantarjian HM; Larson RA; Guilhot F; O'Brien SG; Mone M; Rudoltz M; Krahnke T; Cortes J; Druker BJ. Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase. *Cancer* 2009,**115** 3 551-560.
- 4.1.2. O'Brien SG; Guilhot F; Goldman JM; Hochhaus A; Hughes TP; Radich JP; Rudoltz M; Filian J; Gathmann I; Druker BJ; Larson RA. Seven year follow-up of the International Randomized Study of Interferon Versus ST1571 (IRIS) demonstrates durable efficacy and long-term safety of imatinib in patients (pts) with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP). *British Journal of Haematology* 2009,**145** Supplement 1 40-41 no. 102.
- 4.1.3. Hochhaus A; O'Brien SG; Guilhot F; Druker BJ; Branford S; Foroni L; Goldman JM; Muller MC; Radich JP; Rudoltz M; Mone M; Gathmann I; Hughes TP; Larson RA. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. *Leukemia* 2009,**23** 6 1054-1061.
- 4.1.4. Hochhaus A; Goldman J; Fischer T; O'Brien SG; Reiffers JJ; Mone M; Krahnke T; Talpaz M; Kantarjian HM; Druker B; Sawyers C; Guilhot F; Schiffer CA; Cortes J; Niederwieser DW; Gambacorti-Passerini C; Stone RM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- $\alpha$  treatment. *Blood* 2008,**111** 3 1039-1043.
- 4.1.5. Hasford J; Lauseker M; Gathmann I; Pffirmann M; Larson RA; Guilhot F; O'Brien SG; Druker BJ; Hchlmann R; Hochhaus A; IRIS Study Grp; German CML Study Grp. Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. *Blood* 2008,**112** 11 739-740 no. 2123.
- 4.1.6. Hasford J; Lauseker M; Gathmann I; Pffirmann M; Larson RA; Guilhot F; O'Brien SG; Druker BJ; Hchlmann R; Hochhaus A; IRIS Study Grp; German CML Study Grp. Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. *Blood* 2008,**112** 11 739-740 no. 2123.
- 4.1.7. Larson RA; Druker BJ; Guilhot F; O'Brien SG; Riviere GJ; Krahnke T; Gathmann I; Wang YF. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. *Blood* 2008,**111** 8 4022-4028.
- 4.1.8. Al Attar H; Norden J; O'Brien SG; Monkman A. Improved single nucleotide polymorphisms detection using conjugated polymer/surfactant system and peptide nucleic acid. *Biosensors and Bioelectronics* 2008,**23** 10 1466-1472.
- 4.1.9. O'Brien SG; Guilhot F; Goldman JM; Hochhaus A; Hughes TP; Radich JP; Rudoltz M; Filian J; Gathmann I; Druker BJ; Larson RA. International Randomized Study of Interferon Versus ST1571 (IRIS) 7-year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM). *Blood* 2008,**112** 11 76 no. 186.
- 4.1.10. Feldman EJ; Lipton JH; Maloisel F; Colombat P; Martinelli G; Nielsen JL; Petersdorf S; Guilhot F; Barker J; Kirschmeier P; Frank E; Cortes J; Statkevich P; Zhu Y; Loechner S; List A; DeAngelo DJ; Holyoake T; Simonsson B; O'Brien SG; Reiffers J; Turner AR; Roboz GJ. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. *Leukemia* 2008,**22** 9 1707-1711.
- 4.1.11. Hughes TP; Hochhaus A; Branford S; Muller MC; Foroni L; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Waltzman RJ; Mone M; Wehrle E; Radich JP; Goldman JM. Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus ST1571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). *Blood* 2008,**112** 11 129-130 no. 334.
- 4.1.12. Müller MC; Saglio G; Lin F; Pfeifer H; Press RD; Tubbs RR; Paschka P; Gottardi E; O'Brien SG; Ottmann OG; Stockinger H; Wieczorek L; Merx K; König H; Schwindel U; Hehlmann R; Hochhaus A. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. *Haematologica* 2007,**92** 7 970-973.
- 4.1.13. Kantarjian HM; Druker BJ; Guilhot F; Cortes J; O'Brien SG; Krahnke T; Larson RA. Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP). *Blood* 2007,**110** 11 317A no. 1047.
- 4.1.14. Larson RA; Druker BJ; Guilhot F; O'Brien SG; Krahnke T; Gathmann I; Wang YF. Imatinib plasma concentration and sokal risk score are independently prognostic for complete cytogenetic response (CCyR) in patients with chronic phase chronic myeloid leukemia (CML-CP). *Blood* 2007,**110** 11 574A-575A no. 1935.
- 4.1.15. Hochhaus A; Druker BJ; Larson RA; O'Brien SG; Gathmann I; Guilhot F. IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), treated with imatinib. *Blood* 2007,**110** 11 15A-16A no. 25.
- 4.1.16. Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. *Blood* 2007,**110** 10 3540-3546.
- 4.1.17. Le Coutre P; Giles FJ; Apperley J; Ottmann OG; Gattermann N; O'Brien SG; Kuliczowski K; Larson RA; Kim DW; Haque A; Gallagher N; Baccarani M; Kantarjian HM. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. *Blood* 2007,**110** 11 145A no. 471.
- 4.1.18. Boddy, A. V.; Sludden, J.; Griffin, M. J.; Garner, C.; Kendrick, J.; Mistry, P.; Dutreix, C.; Newell, D. R.; O'Brien, S. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. *Clinical Cancer Research* 2007,**13** 14 4164-4169.
- 4.1.19. Holtick U; Marshall SR; O'Brien SG; Collin MP. Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia. *Blood* 2007. ,**110** 13 4622-4623.
- 4.1.20. Guilhot F; Larson RA; O'Brien SG; Gathmann I; Druker BJ. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. *Blood* 2007,**110** 11 16A no. 27.



10<sup>th</sup> February 2010